Generalized anxiety disorder: how to treat, and for how long?

References

• Carter RM, Wittchen HU, Pfister H, Kessler RC. One year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety 2001; 13: 78–88
   PubMed Web of Science ®Google Scholar
• Wittchen, HU, Hoyer, J. Generalized anxiety disorder: Nature and course. J Clin Psychiatry 2001;62((Suppl 11)):15–19; discussion 20–1.
   PubMedGoogle Scholar
• Kessler RC, Chiu WT, Demler O, Walters E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617–27
   PubMed Web of Science ®Google Scholar
• Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatric Scand 2004; 109(Suppl 420)21–7
   Google Scholar
• Wittchen HU, Carter RM, Pfister H, et al. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 2000; 13: 319–28
   Google Scholar
• Beekman AT, Bremmer MA, Deeg DJ, et al. Anxiety disorders in late life: a report from the longitudinal Aging Study Amsterdam. Int J Geriatr Psychiatry 1998; 13: 717–26
   PubMed Web of Science ®Google Scholar
• Barlow DH, Blanchard EB, Vermilyea JA, et al. Generalized anxiety disorder: Description and reconceptualization. Am J Psychiatr 1986; 143: 40–4
   PubMedGoogle Scholar
• Blazer DG, Hughes D, George LK, . Generalized anxiety disorder. Psychiatric disorders in America: The ECA study, LN Robins, DA Regier, et al. The Free Press, New York 1991; 180–203
   Google Scholar
• Le Roux H, Gatz M, Wetherell JL. Age at onset of generalized anxiety disorder in older adults. Am J Geriatr Psychiatry 2005; 13: 23–30
   Web of Science ®Google Scholar
• Yonkers KA, Dyck IR, Warshaw M, Keller MB. Factors predicting the clinical course of generalized anxiety disorder. Br J Psychiatr 2000; 176: 544–49
   PubMed Web of Science ®Google Scholar
• Weiller E, Bisserbe JC, Maier W, et al. Prevalence and recognition of anxiety syndromes in five European primary care settings: A report from the WHO study on psychological problems in general health care. Br J Psychiatr Suppl 1998; 34: 18–23
   Google Scholar
• Culpepper L. Generalized anxiety disorder in primary care: Emerging issues in management and treatment. J Clin Psychiatry 2002; 63(Suppl 8)35–42
   PubMed Web of Science ®Google Scholar
• Keller MB. The long-term clinical course of generalized anxiety disorder. J Clin Psychiatr 2002; 63(Suppl 8)11–16
   PubMedGoogle Scholar
• Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 2002; 3: 171–99
   PubMedGoogle Scholar
• Davidson JR. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2001; 62(Suppl 11)46–50
   PubMedGoogle Scholar
• NICE. 2004. Clinical Guideline 22. Anxiety management of anxiety (panic disorder, with or without agoraphobia, and generalized anxiety disorder) in adults in primary, secondary, and community care, Issue date December 2004. www.nice.orh.uk/CG022NICEguideline.
   Google Scholar
• Allgulander C, Bandelow B, Hollander E, et al. World Council of Anxiety. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 2003; 8(Suppl 1)53–61
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychopharmacol 2005; 8: 293–302
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 355–64
   PubMed Web of Science ®Google Scholar
• Blazer D, Hughes D, George LK. Stressful life events and the onset of a generalized anxiety syndrome. Am J Psychiatry 1987; 144: 1178–83
   PubMed Web of Science ®Google Scholar
• Rynn MA, Brawman-Mintzer O. Generalized anxiety disorder: acute and chronic treatment. CNS Spectr 2004; 9: 716–23
   PubMed Web of Science ®Google Scholar
• Kapczinski F, Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev 2003; 2: CD003592
   Google Scholar
• Ballenger JC. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder. J Clin Psychiatry 2001; 62(Suppl 19)11–19
   PubMedGoogle Scholar
• Brunello N, den Boer JA, Judd LL, et al. Social phobia: Diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. J Affect Disord 2000; 60: 61–74
   PubMed Web of Science ®Google Scholar
• Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999; 60: 101–6
   PubMed Web of Science ®Google Scholar
• Stocchi F, Nordera G, Jokinen RH, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatr 2003; 64: 250–8
   PubMed Web of Science ®Google Scholar
• Allgulander, C, Huuson, AKT, Florea, I. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2005;9:1–11, [ePub ahead of print].
   Google Scholar
• Davidson JR, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004; 19: 234–40
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Huuson AKT, Maehlum E. Escitalopram and paroxetine compared to placebo in generalized anxiety disorder. Eur Neuropsychopharmacol 2004; 14(Suppl 3)311–12
   Google Scholar
• Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: Pooled results from double-blind, placebo-controlled trials. J Affect Disord 2005; 87: 161–7
   PubMed Web of Science ®Google Scholar
• Stein DJ, Andersen HF, Goodman WK. Escitalopram for the treatment of GAD: Efficacy across different subgroups and outcomes. Ann Clin Psychiatry 2005; 17: 71–5
   PubMedGoogle Scholar
• Gorman JM. Treatment of generalized anxiety disorder. J Clin Psychiatry 2002; 63(Suppl 8)17–23
   Google Scholar
• Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240–9
   PubMed Web of Science ®Google Scholar
• Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62: 1022–30
   PubMed Web of Science ®Google Scholar
• Kasper, S (USA) , Blagden, M, Seghers, S, et al. A placebo controlled study of pregabalin and venlafaxine treatment of GAD. Poster presented at: Annual Meeting of the American Psychiatric Association; May 21, 2002, Philadelphia, , PA, ; 2002.
   Google Scholar
• Montgomery SA, Mahe V, Haudiquet V, Hackett D. Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: Results of a survival analysis. J Clin Psychopharmacol 2002; 22: 561–7
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Bose A, Change CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005; 17: 65–69
   PubMedGoogle Scholar